Evvy will use a $40 million Series B, led by Catalio Capital Management, to expand the laboratory testing and research infrastructure underpinning its vaginal microbiome service. The financing is aimed at growing the company’s dataset and clinical research capabilities, resources Evvy says are necessary to sharpen personalised care and uncover new female health biomarkers.
Founded in 2021 by Priyanka Jain, Laine Bruzek and Pita Navarro, Evvy sells an at‑home molecular test that the company says pairs CLIA and CLEP certification with metagenomic next‑generation sequencing from a single swab. Customers mail samples to Evvy’s lab, where the material is sequenced, results are routed to clinicians on the platform for review, and patients can view findings in a portal.
“When a patient receives their results, they are presented alongside a diagnosis, clinical interpretation, and a clear path of next steps, including personalized prescription care when relevant,” CEO and co‑founder Priyanka Jain said.
Evvy reports it now serves more than 100,000 patients and works with 3,000 practitioners across the United States. Jain highlighted the startup’s peer‑reviewed output and genomic discoveries as proof the platform can drive research. “We’ve generated 15-peer reviewed publications and abstracts, identified novel BV subtypes, and discovered hundreds of previously uncatalogued vaginal microbiome genomes,” she said.
The company says its research focus is to connect microbial signals with symptoms, interventions and outcomes so care improves as the dataset grows. Evvy has begun combining that dataset with artificial intelligence; in May it launched EvvyAI, an assistant meant to translate microbiome results into user guidance and to point patients to clinicians when needed. Jain argued models for women’s health require new biological data at scale, because existing datasets under‑represent female biology.
Evvy is also building evidence linking the vaginal microbiome to fertility and other reproductive outcomes, including infertility, gynecological cancer, preterm birth, IVF success rates and recurrent pregnancy loss. Last year it started a prospective study deploying its tests inside IVF clinics.
Competitors named by the company include JunoBio, TinyHealth and Daye. Jain voiced a longer term ambition for routine, at‑home screening that provides regular, data‑rich insights across infections, inflammation, fertility, PCOS, endometriosis, premenopause and HPV progression. The new capital is intended to speed data collection and expand clinical partnerships Evvy views as essential to reach that goal, and to move the company from single tests toward broader, longitudinal monitoring.
